Ipilimumab with fotemustine in metastatic melanoma
Mené sur 86 patients atteints d'un mélanome métastatique avec ou sans métastases cérébrales, cet essai de phase II évalue l'activité clinique d'un traitement combinant ipilimumab et fotemustine
Ipilimumab—an antibody against cytotoxic T-lymphocyte-associated protein 4—was the first systemic treatment in unresectable metastatic melanoma to be proven to extend overall survival. No previous phase 3 trial had shown any significant survival benefit for systemic treatments in melanoma. Two phase 3 clinical trials (one comparing ipilimumab with gp100 vaccination3 and one ipilimumab plus dacarbazine versus dacarbazine alone4) showed a significant improvement of 10% in overall survival after 2—4 years. In these two trials, different doses of 3 and 10 mg/kg were used. 3 mg/kg ipilimumab every 3 weeks for four treatment cycles has been approved in Europe and the USA for treatment of unresectable metastatic melanoma. However, the two previous trials raised questions about whether this immunotherapy should be combined with cytotoxic drugs and whether increased doses and reinduction or maintenance treatment would increase effectiveness...
The Lancet Oncology , commentaire en libre accès, 2011